was discontinued, and he was cautioned not to start it again.
dimesylate, a class II stimulant, was approved in 2012 by the Food and Drug Administration for adult ADHD.
Drug interactions: Lisdexamfetamine
may alter the therapeutic effects of adrenergic blockers, tricyclic antidepressants, antihistamines, antihypertensives, ethosuximide, meperidine, norepinephrine, phenobarbital, phenytoin, and Veratrum alkaloids.
Patients were assigned to placebo or to lisdexamfetamine
at 30, 50, or 70 mg/day.
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine
dimesylate in adults with attention-deficit/hyperactivity disorder.
Dimesylate In Children And Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo- And Active Controlled, Dose-Optimized Study In Europe.
2, 2015 /PRNewswire-USNewswire/ -- The United States Food and Drug Administration (FDA) recently approved lisdexamfetamine
dimesylate, under the brand name Vyvanse, to treat moderate to severe binge eating disorder (BED) in adults, a first of its kind prescription drug specifically indicated for BED.
The Court's summary judgment ruling concerning Shire's motion included 18 patent claims from four of the FDA Orange Book-listed patents for Vyvanse, which cover Vyvanse's active ingredient, the lisdexamfetamine
dimesylate compound, and a method of using lisdexamfetamine
dimesylate for the treatment of ADHD.
Long-acting preparations--extended-release and transdermal formulations and the prodrug lisdexamfetamine
(Vyvanse)--have minimal potential to be misused and are preferable to immediate-release forms, Dr.
Watson"), advising of the filing of Abbreviated New Drug Applications ("ANDA") by each company for generic version of all strengths of lisdexamfetamine
dimesylate capsules, VYVANSE.
SAN DIEGO -- Lisdexamfetamine
, the recently approved once-daily medication for attention-deficit/hyperactivity disorder that appears to have low abuse potential, was safe and effective when given for a full year, and guanfacine, an investigational alpha-2A-adrenoreceptor, produced substantial improvement in a phase III trial, according to studies presented at the annual meeting of the American Psychiatric Association.
In addition, lisdexamfetamine
dimesylate is currently available in eight European countries indicated as part of a comprehensive treatment programme for ADHD in children and adolescents 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate (brand names Elvanse[sup.